Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs

Phase 3 ◽

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy: Table 1.

10.1136/annrheumdis-2016-eular.1239 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 412.2-413 ◽

Cited By ~ 1

Author(s):

E. Keystone ◽

P. Taylor ◽

Y. Tanaka ◽

C. Gaich ◽

A.M. DeLozier ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Methotrexate Therapy ◽

Inadequate Response ◽

Phase 3 ◽

THU0215 Effects of tofacitinib on patient-reported outcomes in a phase 3 study of chinese patients with active rheumatoid arthritis and an inadequate response to dmards

10.1136/annrheumdis-2017-eular.2273 ◽

2017 ◽

Author(s):

Z Li ◽

Y An ◽

G Li ◽

L Wang ◽

K Kwok ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Chinese Patients ◽

Inadequate Response ◽

Phase 3 ◽

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

Rheumatology ◽

10.1093/rheumatology/kev442 ◽

2016 ◽

Vol 55 (6) ◽

pp. 1031-1041 ◽

Cited By ~ 33

Author(s):

Vibeke Strand ◽

Ronald F. van Vollenhoven ◽

Eun Bong Lee ◽

Roy Fleischmann ◽

Samuel H. Zwillich ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Placebo Patient ◽

Phase 3 ◽

THU0151 Effects of tofacitinib (CP-690,550), an oral janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis:

10.1136/annrheumdis-2012-eular.2116 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 206.2-206 ◽

Cited By ~ 4

Author(s):

R.F. van Vollenhoven ◽

G. Wallenstein ◽

E.B. Lee ◽

R. Fleischmann ◽

S.H. Zwillich ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Kinase Inhibitor ◽

Janus Kinase ◽

Phase 3 ◽

Janus Kinase Inhibitor ◽

THU0258 Oral Start: Effects of the Oral JAK Inhibitor Tofacitinib Monotherapy Versus Methotrexate on Patient-Reported Outcomes in the Phase 3 Oral Start Trial of Active Rheumatoid Arthritis

10.1136/annrheumdis-2013-eular.786 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A252.3-A253 ◽

Cited By ~ 3

Author(s):

V. Strand ◽

R. Fleischmann ◽

R. E. Alten ◽

T. Koncz ◽

S. H. Zwillich ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Jak Inhibitor ◽

Phase 3 ◽

Patient Reported ◽

Start Trial

Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials

Rheumatology and Therapy ◽

10.1007/s40744-021-00415-8 ◽

2022 ◽

Author(s):

Dalton Sholter ◽

Jianmin Wu ◽

Bochao Jia ◽

Hong Zhang ◽

Kirstin Griffing ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase 3 ◽

Two Phase ◽

Patient Reported ◽

Post Hoc

Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial

Arthritis Care & Research ◽

10.1002/acr.22453 ◽

2015 ◽

Vol 67 (4) ◽

pp. 475-483 ◽

Cited By ~ 34

Author(s):

Vibeke Strand ◽

Gerd R. Burmester ◽

Cristiano A. F. Zerbini ◽

Charles A. Mebus ◽

Samuel H. Zwillich ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Phase Iii ◽

Line Treatment ◽

Phase Iii Trial ◽

Active Rheumatoid Arthritis Patient ◽

Patient Reported ◽

Third Line ◽

Third Line Treatment

Improvements in Patient-Reported outcomes Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naive Patients with Severe, Active and Progressive Rheumatoid Arthritis: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study

Value in Health ◽

10.1016/j.jval.2015.09.2660 ◽

2015 ◽

Vol 18 (7) ◽

pp. A707-A708 ◽

Cited By ~ 2

Author(s):

P Emery ◽

C Bingham ◽

G Burmester ◽

V Bykerk ◽

D Furst ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Certolizumab Pegol ◽

Phase 3 ◽

Double Blind ◽

SAT0165 Improvements in Patient-Reported Outcomes and Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study

10.1136/annrheumdis-2015-eular.1499 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 712.2-713 ◽

Cited By ~ 1

Author(s):

P. Emery ◽

C.O. Bingham ◽

G.-R. Burmester ◽

V.P. Bykerk ◽

D.E. Furst ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Early Rheumatoid Arthritis ◽

Certolizumab Pegol ◽

Phase 3 ◽

Double Blind ◽

Patient Reported ◽

Household Productivity

THU0180 Relationship Between Different Clinical Measurements and Patient-Reported Outcomes: Results from a Phase 3 Study of Tofacitinib or Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis

10.1136/annrheumdis-2015-eular.3928 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 259.2-260

Author(s):

R. Fleischmann ◽

V. Strand ◽

B. Wilkinson ◽

K. Kwok ◽

E. Bananis

Keyword(s):

Rheumatoid Arthritis ◽

Phase 3 ◽

Patient Reported ◽

Clinical Measurements